Acurx Financial Statements From 2010 to 2026

ACXP Stock  USD 2.76  0.27  10.84%   
Analyzing historical trends in various income statement and balance sheet accounts from Acurx Pharmaceuticals' financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Acurx Pharmaceuticals' valuation are summarized below:
Market Capitalization
5.2 M
Earnings Share
(8.18)
There are currently ninety fundamental signals for Acurx Pharmaceuticals LLC that can be evaluated and compared over time across rivals. Investors and active traders are advised to validate Acurx Pharmaceuticals' prevailing fundamental performance against the performance between 2010 and 2026 to make sure the trends are evolving in the right direction.
Check Acurx Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Acurx Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 17 M, Interest Expense of 1.3 K or Selling General Administrative of 7.4 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 26.31. Acurx financial statements analysis is a perfect complement when working with Acurx Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Acurx Stock
Check out the analysis of Acurx Pharmaceuticals Correlation against competitors.

Acurx Pharmaceuticals Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets7.3 M4.4 M4.4 M
Slightly volatile
Other Current Liabilities2.1 M3.7 M1.9 M
Slightly volatile
Total Current Liabilities2.1 M3.7 M1.9 M
Slightly volatile
Total Stockholder Equity525.9 K553.6 K2.2 M
Slightly volatile
Net Tangible Assets6.4 M8.4 M3.5 M
Slightly volatile
Accounts Payable3.3 K3.4 K11.4 K
Slightly volatile
Cash7.1 M4.3 M4.3 M
Slightly volatile
Cash And Short Term Investments7.1 M4.3 M4.3 M
Slightly volatile
Common Stock Total Equity14.6 M19 M12.7 M
Slightly volatile
Common Stock Shares Outstanding643.4 K979.3 K554.5 K
Slightly volatile
Liabilities And Stockholders Equity7.3 M4.4 M4.4 M
Slightly volatile
Other Current Assets158.2 K115.1 K92.3 K
Slightly volatile
Other Stockholder Equity54.8 M78.1 M30.3 M
Slightly volatile
Total Liabilities2.1 M3.7 M1.9 M
Slightly volatile
Net Invested Capital672 K707.4 K5.3 M
Slightly volatile
Total Current Assets7.3 M4.4 M4.4 M
Slightly volatile
Capital Stock14.6 K15.3 K6.9 M
Slightly volatile
Net Working Capital525.9 K553.6 K2.2 M
Slightly volatile
Common Stock14.6 K15.3 K6.9 M
Slightly volatile
Short and Long Term Debt Total53.2 K59.9 K65.3 K
Slightly volatile
Long Term Debt39.9 K44.9 K49 K
Slightly volatile
Short and Long Term Debt13.3 K15 K16.3 K
Slightly volatile
Short Term Debt13.3 K15 K16.3 K
Slightly volatile
Other Assets136.4 M136.1 M247.2 M
Slightly volatile
Net Receivables72.1 K46 K116.3 K
Slightly volatile

Acurx Pharmaceuticals Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization17 M16.2 M4.4 M
Slightly volatile
Selling General Administrative7.4 M10 M4.7 M
Slightly volatile
Other Operating Expenses11.8 M16.2 M8.6 M
Slightly volatile
Research Development4.4 M6.2 M3.9 M
Slightly volatile
Total Operating Expenses11.8 M16.2 M8.6 M
Slightly volatile
Selling And Marketing Expenses9.5 B10 B8.7 B
Slightly volatile

Acurx Pharmaceuticals Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation3.6 MM2.1 M
Slightly volatile
Begin Period Cash Flow6.8 M8.6 M4.2 M
Slightly volatile
Other Cashflows From Financing Activities179.7 K189.2 K1.3 M
Pretty Stable
Issuance Of Capital Stock4.9 M5.8 M5.2 M
Pretty Stable
Total Cash From Financing Activities7.7 M7.6 M5.7 M
Slightly volatile
End Period Cash Flow7.1 M4.3 M4.3 M
Slightly volatile
Change To Netincome3.8 M3.8 M2.1 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
PTB Ratio26.3125.9249.7375
Slightly volatile
Book Value Per Share0.790.834.4021
Pretty Stable
PB Ratio26.3125.9249.7375
Slightly volatile
Cash Per Share4.765.018.2792
Pretty Stable
Income Quality0.510.660.6496
Slightly volatile
Net Debt To EBITDA0.290.30.4705
Very volatile
Current Ratio1.31.372.8388
Pretty Stable
Tangible Book Value Per Share0.790.834.4021
Pretty Stable
Shareholders Equity Per Share0.790.834.4021
Pretty Stable
Debt To Equity0.01970.02220.0242
Slightly volatile
Graham Net Net0.640.684.2198
Pretty Stable
Average Receivables51.7 K58.1 K63.4 K
Slightly volatile
Interest Debt Per Share0.10.120.1313
Slightly volatile
Debt To Assets0.01650.01860.0203
Slightly volatile
Price Book Value Ratio26.3125.9249.7375
Slightly volatile
Ebt Per Ebit0.790.90.9772
Slightly volatile
Company Equity Multiplier5.935.643.1714
Slightly volatile
Long Term Debt To Capitalization0.01450.01630.0178
Slightly volatile
Total Debt To Capitalization0.01920.02160.0236
Slightly volatile
Debt Equity Ratio0.01970.02220.0242
Slightly volatile
Quick Ratio1.31.372.8388
Pretty Stable
Cash Ratio1.251.312.7743
Pretty Stable
Price To Book Ratio26.3125.9249.7375
Slightly volatile
Debt Ratio0.01650.01860.0203
Slightly volatile
Price Fair Value26.3125.9249.7375
Slightly volatile

Acurx Pharmaceuticals Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap15.1 M15.9 M40.7 M
Slightly volatile
Enterprise Value11.1 M11.7 M37.7 M
Slightly volatile

Acurx Fundamental Market Drivers

Acurx Upcoming Events

21st of March 2024
Upcoming Quarterly Report
View
10th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
21st of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Acurx Pharmaceuticals Financial Statements

Acurx Pharmaceuticals shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Acurx Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Acurx Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Acurx Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year

Pair Trading with Acurx Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Acurx Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Acurx Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving against Acurx Stock

  0.81FTV Fortive CorpPairCorr
  0.8MRK Merck CompanyPairCorr
  0.79TRV The Travelers CompaniesPairCorr
  0.74CSCO Cisco SystemsPairCorr
  0.71AMGN Amgen IncPairCorr
The ability to find closely correlated positions to Acurx Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Acurx Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Acurx Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Acurx Pharmaceuticals LLC to buy it.
The correlation of Acurx Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Acurx Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Acurx Pharmaceuticals LLC moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Acurx Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Acurx Stock Analysis

When running Acurx Pharmaceuticals' price analysis, check to measure Acurx Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acurx Pharmaceuticals is operating at the current time. Most of Acurx Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Acurx Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acurx Pharmaceuticals' price. Additionally, you may evaluate how the addition of Acurx Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.